

e-therapeutics plc
("e-therapeutics" or the "Company")

Notice of Interim Results

Oxford, UK, 11 October 2021 - e-therapeutics plc (AIM: ETX; OTCQX: ETXPF), a specialist in computational drug discovery with a focus on developing RNA interference ("RNAi") therapeutics, will announce its interim results for the six months ended 31 July 2021 on Tuesday 26 October 2021.

Enquiries:

e-therapeutics plc
Ali Mortazavi, CEO
Karl Keegan, CFO

Tel: +44 (0)1993 883 125
www.etherapeutics.co.uk

SP Angel Corporate Finance LLP
Nominated Adviser and Broker
Matthew Johnson/Caroline Rowe (Corporate Finance)
Vadim Alexandre/Rob Rees (Corporate Broking)

Tel: +44(0)20 3470 0470

About e-therapeutics plc

e-therapeutics plc is an Oxford, UK-based company integrating computational power and biology to accelerate the discovery of life-transforming medicines. The Company has developed and validated a powerful, disease and modality agnostic computational approach to drug discovery, leveraging its industry-leading expertise in network biology to fully capture and interrogate human disease complexity.

The Company's multi-disciplinary team builds computational models of biological functions to transform the search for new medicines, interventions, mechanisms and genetic support. Its biology-led *in silico* laboratory enables rapid hypothesis generation and phenotypic screening of millions of compounds leading to 100-1,000x higher hit rates in the wet lab and successful mode of action elucidation. Novel targets can also be identified, prioritised and assessed. Harnessing internal target gene discoveries, e-therapeutics is currently building an in-house pipeline of RNAi based medicines, using its proprietary GalNAc-siRNA technology.

e-therapeutics has deployed and validated its disease-agnostic computational drug discovery platform both in house and with partners, including Novo Nordisk, Galapagos NV and a US-based, top five pharmaceutical company.